Novel AD biomarker based on platelets tau: Expanding to plasma detection

Alzheimer’s disease (AD) is the most prevalent cause of dementia in the elderly. One of the major drawbacks of this disease is the lack of molecular biomarkers that could provide of an early detection, as the ones currently available are invasive (CSF biomarkers), not cost‐efficient (neuroimaging, PET scan) and do not provide an early detection. In this work we propose the novel biomarker Alz‐tau®, based on platelet tau, as a non‐invasive and cost‐efficient way for early detection of pathological events that may lead Alzheimer’s disease.